Nectar Lifesciences Balance Sheet
- Market cap
- ₹201 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹7.44 – ₹13.95
As of FY25, Nectar Lifesciences had total assets of ₹130 crore and borrowings of ₹24.08 crore, against shareholders' equity of ₹210 crore — a debt-to-equity ratio of 0.35.
Nectar Lifesciences balance sheet
As at each financial year end, newest first. H1 = half-year.
| Item | FY25 |
|---|---|
| Equity capital | 120 |
| Reserves | 90.3 |
| Borrowings | 24.08 |
| Other liabilities | 16.05 |
| Total liabilities | 130 |
| Fixed assets | 70.23 |
| Capital work in progress | 45 |
| Investments | 30.1 |
| Other assets | 30.1 |
| Total assets | 130 |
Balance sheet ratios
- Debt to equity
- 0.35
- Book value per share
- ₹3.62
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Nectar Lifesciences balance sheet — frequently asked questions
What is the total debt of Nectar Lifesciences?
Nectar Lifesciences reported borrowings of ₹24.08 crore as of FY25.
What is Nectar Lifesciences' debt-to-equity ratio?
Based on the FY25 balance sheet, Nectar Lifesciences' debt-to-equity ratio is 0.35 — borrowings of ₹24.08 crore against equity capital and reserves of ₹210 crore.
What are Nectar Lifesciences' total assets?
Nectar Lifesciences' total assets were ₹130 crore as of FY25, including fixed assets of ₹70.23 crore and investments of ₹30.1 crore.
What is the book value per share of Nectar Lifesciences?
The book value per share of Nectar Lifesciences is ₹3.62, based on the latest reported balance sheet.
Same Data For Peers
Trade Nectar Lifesciences With ATS
Track NECLIFE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.